Skip to main content

Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Limited Progress on QoL Goals Reported for Persons With HIV Aged 50 Years and Older

FRIDAY, Sept. 13, 2024 -- For persons diagnosed with HIV (PWH) aged 50 years and older, progress on quality of life (QoL) goals is limited, according to a...

Boar's Head Will Close Virginia Plant Linked to Listeria-Tainted Deli Meats

FRIDAY, Sept. 13, 2024 -- Boar's Head announced Friday that its Jarratt, Va. deli meat manufacturing plant, found to be the source of a deadly outbreak of...

Ozempic or Saxenda for Weight Loss: Which Works Best?

FRIDAY, Sept. 13, 2024 -- Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated...

Predictive Models for HTN Screening Developed Using Speech Recordings

FRIDAY, Sept. 13, 2024 -- Predictive models for hypertension screening have been developed using speech recordings, with accuracies up to 84 percent for women...

Sulthiame Beneficial for Symptoms of Obstructive Sleep Apnea

FRIDAY, Sept. 13, 2024 -- Sulthiame (STM) is beneficial for improving symptoms of obstructive sleep apnea (OSA), according to a study presented at the European...

Time-Restricted Eating Helps to Improve Diabetes Outcomes

FRIDAY, Sept. 13, 2024 -- Time-restricted eating (TRE) may improve diabetes outcomes, independent of energy intake, according to a study presented at the...

Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes

FRIDAY, Sept. 13, 2024 -- Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2 diabetes who...

1 in 3 Store-Bought Cinnamon Samples Tested Have Elevated Lead Levels

FRIDAY, Sept. 13, 2024 -- One third of cinnamon products tested by Consumer Reports contained elevated levels of lead, the watchdog agency warned...

Over 5 Million Americans Could Benefit If Psilocybin Approved for Depression: Study

FRIDAY, Sept. 13, 2024 -- Over 5 million Americans could benefit if the U.S. Food and Drug Administration approves the "magic mushroom" psychedelic psilocybin...

Source of Missouri Bird Flu Case Still Unknown, Could Be a 'One-Off': CDC

FRIDAY, Sept. 13 , 2024 -- In a case that continues to confound scientists, U.S. health officials said Thursday that they still don't know how a Missouri...

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and...

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has...

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food...

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies...

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Spring House, Pa. (August 29, 2024) – Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and...

Emergent BioSolutions’ ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA)...

Telix Submits NDA for TLX101-CDx (Pixclara) Brain Cancer Imaging Agent

MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New...

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on...

FDA Approves Pavblu (aflibercept-ayyh), a Biosimilar to Eylea

August 23, 2024 – The U.S. Food and Drug Administration (FDA) has announced the approval of Pavblu (aflibercept-ayyh) 2 mg injection (single-dose...

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases...

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat...

Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 Shows Significant Results in Preclinical Studies

LEHI, Utah., Sept. 12, 2024. Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the...

Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3 trial...

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

INDIANAPOLIS, Sept. 10, 2024. Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora...

Browse by news type

Drugs.com Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Disclaimer

This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.